Isarna Therapeutics
Latest round
- Series E
Last raised
- Feb 2010
Total raised
- $18M
Investors
- 3
About Isarna Therapeutics
Founded in 1998 in Munich, Germany, Isarna Therapeutics is engaged in developing innovative therapies targeting TGF-ß pathways.618 mn.Isarna Therapeutics specializes in developing antisense oligonucleotide therapies, primarily targeting TGF-ß signaling pathways. Their lead product, ISTH0036, is in Phase 2a clinical trials focused on treating ophthalmological conditions, including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Additionally, Isarna's portfolio aims to provide treatment options for fibrotic liver diseases such as non-alcoholic steatohepatitis (NASH) and various cancers.Isarna Therapeutics operates under a business model that emphasizes partnerships and collaborations with research institutions and pharmaceutical companies. Revenue is generated through licensing agreements, clinical trial collaborations, and anticipated future product sales. The company engages directly with healthcare providers and institutions that utilize their antisense therapies in clinical environments. They aim to expand their market presence specifically in North America and Europe by enhancing collaborations with clinical centers specializing in their therapeutic areas. The company is focused on launching additional products targeting TGF-ß pathways, with an emphasis on addressing unmet medical needs in both ophthalmology and liver diseases.
Who invested in Isarna Therapeutics
3 investors across 2 rounds
See all investors in Isarna Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Isarna Therapeutics
Who invested in Isarna Therapeutics?
Isarna Therapeutics has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Isarna Therapeutics raised?
Isarna Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Isarna Therapeutics last raise money?
Isarna Therapeutics's most recent round on record is a Series E, in Feb 2010.
What does Isarna Therapeutics do?
Founded in 1998 in Munich, Germany, Isarna Therapeutics is engaged in developing innovative therapies targeting TGF-ß pathways.
Where is Isarna Therapeutics headquartered?
Isarna Therapeutics is headquartered in Munich, Germany.
Which VCs invest in companies like Isarna Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Isarna Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Isarna Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.